A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
← catalyst calendarNCT07286175 · readout ≤ 468 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
400estimated
Sites
87
Countries
Argentina, Brazil, China +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-24 | actual | When the study began enrolling |
| Primary completion | Nov 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bipolar Disorder
Interventions
- Drug: Brenipatide — also filed as LY3537031
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion
measured Randomization up to at least 6 months
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed